Abstract:of the rectum and underwent proctectomy with ileostomy. To the Editor: She subsequently died of liver failure at age 48 and was found at autopsy to have advanced cholangiocarcinoma complicatUlricka Broomé and her colleagues have suggested that ing PSC. the risk of colon cancer in patients with ulcerative colitis (UC) is potentiated by the presence of primary sclerosing CASE 2 cholangitis (PSC). I have observed a similar association At the age of 10 years, this girl presented with total ulceraamongst my patients with PSC in a city in South Wales with tive colitis. There was no family history of bowel or liver a population of 250,000. disease. Six years later she suffered transient jaundice and Twenty-two patients (13 men, 9 women) with PSC of meher liver function tests remained abnormal thereafter. At the dian age 42 years (range, 21-78 years) have been followed age of 23, she developed colonic obstruction and underwent between 1984 and 1995. Median duration of follow-up is 7 right hemicolectomy for Duke’s B cancer of the ascending years (range, 1-11 years). Of these, 6 have died, 15 are under colon. Eight years later she became jaundiced again and PSC regular review, and 1 has moved to another city but is alive was diagnosed at ERCP (diffuse stricturing and beading of and well. Four died of cholangiocarcinoma, 2 died of liver intrahepatic bile duct). She later bled from esophageal varifailure. ces and underwent successful liver transplantation at age 35. Fourteen of twenty-two have colitis (UC, 13; Crohn’s, 1). She is currently well 5 years after the transplantation but Four have developed cholangiocarcinoma aged between 47 has active colitis in the remaining colon without evidence of and 78 years and all have subsequently died. Three colon dysplasia. cancers have been diagnosed in two patients, one of whom The finding of three colon cancers in two young patients also developed cholangiocarcinoma. The case histories are from a group of 14 UC/PSC sufferers represents a greater given below: cancer risk than generally associated with UC alone and is very similar to that reported by Broomé et al. (6 cancers in CASE 1 40 UC/PSC patients). These observations from South Wales A woman with no family history of bowel or liver disease support the proposed association between PSC and colon candeveloped total ulcerative colitis at the age of 18. She undercer. went emergency colectomy and ileo-rectal anastomosis at the age of 24 for active disease and was found to have a Duke’s A J.G.C. KINGHAM, M.D., F.R.C.P. colon cancer in the resected specimen. This had not produced Consultant Physician symptoms. She underwent thyroidectomy for Grave’s thyroSingleton Hospital toxicosis and also suffered severe asthma and psoriasis. She Wales, UK developed symptomatic icteric PSC at the age of 37 years confirmed by ERCP (intrahepatic strictures and dilatation REFERENCES with a dominant stricture extrahepatically in CBD) when she 1. Broomé U, Söfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis was 37 years old. Four years later, during a routine surveiland ulcerative colitis: evidence for increased neoplastic potential. HEPATOL-

FTO regulates myoblast proliferation by controlling CCND1 expression in an m<SUP>6</SUP>A-YTHDF2-dependent manner

FTO regulates myoblast proliferation by controlling CCND1 expression in an m6A-YTHDF2-dependent manner

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

SPI1-induced Downregulation of FTO Promotes GBM Progression by Regulating Pri-Mir-10a Processing in an M6a-Dependent Manner

M6a Mrna Methylation Controls Autophagy and Adipogenesis by Targeting Atg5 and Atg7

Fat mass and obesity‐associated protein regulates lipogenesis via m 6 A modification in fatty acid synthase mRNA

Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms

FTO Promotes Clear Cell Renal Cell Carcinoma Progression Via Upregulation of PDK1 Through an M6a Dependent Pathway

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

Recruitment of the m6A/Am demethylase FTO to target RNAs by the telomeric zinc finger protein ZBTB48

Dynamic Effects of Fto in Regulating the Proliferation and Differentiation of Adult Neural Stem Cells of Mice.

Effect of demethyltransferase FTO on tumor progression

FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m 6 A modifications of multiple pro-angiogenic factors

Targeted Demethylation of the TGFβ1 mRNA Promotes Myoblast Proliferation via Activating the SMAD2 Signaling Pathway

FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis

N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1 alpha signalling axis

WNT/-catenin-suppressed FTO expression increases m<SUP>6</SUP>A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

Risk of colon cancer in patients with ulcerative colitis is potentiated by the presence of primary sclerosing cholangitis

WNT/β-catenin-suppressed FTO expression increases m 6 A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

m 6 A methylation modulates adipogenesis through JAK2-STAT3-C/EBPβ signaling.

WNT/β-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis